{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:56:15Z","timestamp":1791464175932,"version":"4.3.4"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,3]]},"DOI":"10.18632\/oncotarget.12306","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T19:10:04Z","timestamp":1475089804000},"page":"285-302","source":"Crossref","is-referenced-by-count":56,"title":["Prognostic significance of<i>BRCA<\/i>mutations in ovarian cancer: an updated systematic review with meta-analysis"],"prefix":"10.18632","volume":"8","author":[{"given":"Kai","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"key":"1","first-page":"dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","volume":"106","author":"Rebbeck","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Cole","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"3","first-page":"787143","article-title":"BRCA-associated ovarian cancer: from molecular genetics to risk management","volume":"2014","author":"Turchetti","year":"2014","journal-title":"Biomed Res Int"},{"key":"4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yexcr.2014.07.003","article-title":"Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3","volume":"329","author":"Dantzer","year":"2014","journal-title":"Exp Cell Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Powell","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.dnarep.2014.03.014","article-title":"DNA double-strand break repair pathway choice and cancer","volume":"19","author":"Gautier","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Krivak","year":"2012","journal-title":"Gynecol Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Gore","year":"2008","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13053-015-0044-z","article-title":"Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients","volume":"14","author":"Szczylik","year":"2016","journal-title":"Hered Cancer Clin Pract"},{"key":"10","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","author":"Imhof","year":"2015","journal-title":"Gynecol Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-14-3242","article-title":"Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy","volume":"75","author":"Hautaniemi","year":"2015","journal-title":"Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Fereday","year":"2015","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"e113169","DOI":"10.1371\/journal.pone.0113169","article-title":"A genomic instability score in discriminating nonequivalent outcomes of BRCA1\/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy","volume":"9","author":"Hao","year":"2014","journal-title":"PLoS One"},{"key":"14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Scroggins","year":"2014","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ygyno.2011.12.205","article-title":"Chemotherapy response and survival in serous ovarian cancer patients with BRCA mutations","volume":"125","author":"Krivak","year":"2012","journal-title":"Gynecologic Oncology"},{"key":"16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/annonc\/mdq577","article-title":"Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity","volume":"22","author":"Kauff","year":"2011","journal-title":"Ann Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2002.20.2.463","article-title":"Effect of BRCA mutations on the length of survival in epithelial ovarian tumors","volume":"20","author":"Struewing","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199611073351901","article-title":"Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1","volume":"335","author":"Boyd","year":"1996","journal-title":"N Engl J Med"},{"key":"19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2015.11.009","article-title":"Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","volume":"140","author":"Narod","year":"2016","journal-title":"Gynecol Oncol"},{"key":"20","article-title":"Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis","author":"Sobol","year":"2016","journal-title":"Fam Cancer"},{"key":"21","first-page":"1196","article-title":"Failure of BRCA1 dysfunction to alter ovarian cancer survival","volume":"8","author":"Davis","year":"2002","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.1998.16.2.397","article-title":"Survival of BRCA1 breast and ovarian cancer patients: A population- based study from Southern Sweden","volume":"16","author":"Olsson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0301-2115(01)00318-9","article-title":"Survival analysis in familial ovarian cancer, a case control study","volume":"98","author":"Kenemans","year":"2001","journal-title":"European journal of obstetrics, gynecology, and reproductive biology"},{"key":"24","doi-asserted-by":"crossref","first-page":"e95285","DOI":"10.1371\/journal.pone.0095285","article-title":"The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis","volume":"9","author":"Ma","year":"2014","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Hwang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/IGC.0000000000000247","article-title":"BRCA1\/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer","volume":"24","author":"Janavicius","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"27","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Bowtell","year":"2012","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Zhang","year":"2011","journal-title":"Jama"},{"key":"29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2010.12.354","article-title":"Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations","volume":"121","author":"Powell","year":"2011","journal-title":"Gynecol Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Gonzalez-Angulo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"31","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Gore","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2004.10.011","article-title":"Prevalence and clinical correlations of BRCA1\/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report","volume":"41","author":"Devilee","year":"2005","journal-title":"Eur J Cancer"},{"key":"33","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Karlan","year":"2003","journal-title":"Cancer"},{"key":"34","first-page":"235","article-title":"Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1","volume":"4","author":"Toyoda","year":"1998","journal-title":"Clin Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1038\/srep04026","article-title":"Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status","volume":"4","author":"Konecny","year":"2014","journal-title":"Scientific reports"},{"key":"36","doi-asserted-by":"crossref","first-page":"viii63","DOI":"10.1093\/annonc\/mdt315","article-title":"BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups","volume":"24","author":"Muggia","year":"2013","journal-title":"Ann Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jnci\/djs494","article-title":"Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2","volume":"105","author":"Narod","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"38","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1002\/cncr.26655","article-title":"Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer","volume":"118","author":"Kauff","year":"2012","journal-title":"Cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Sadetzki","year":"2008","journal-title":"J Clin Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10689-006-9112-x","article-title":"Improved survival in BRCA2 carriers with ovarian cancer","volume":"6","author":"Sutphen","year":"2007","journal-title":"Fam Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/ejso.2000.1097","article-title":"Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations","volume":"27","author":"Ponder","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Poynor","year":"2000","journal-title":"Jama"},{"key":"43","first-page":"868","article-title":"Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group","volume":"59","author":"Ponder","year":"1999","journal-title":"Cancer Res"},{"key":"44","unstructured":"Wells, Shea, O'Connell, Peterson, Welch, Losos, Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2000."},{"key":"45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Mazumdar","year":"1994","journal-title":"Biometrics"},{"key":"46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Laird","year":"1986","journal-title":"Control Clin Trials"},{"key":"47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Tweedie","year":"2000","journal-title":"Biometrics"},{"key":"48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Minder","year":"1997","journal-title":"BMJ"},{"key":"49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Altman","year":"2003","journal-title":"BMJ"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T21:47:50Z","timestamp":1749592070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,3]]}},"alternative-id":["12306","27690218"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12306","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}